Belimumab Disease Modifying Anti-rheumatic Drugs,DMARDs Pharmacology Physiotherapy


In this article we will discuss Belimumab (Dosage Overview)

In this article, we will discuss Belimumab (Dosage Overview). So, let’s get started.


Belimumab is indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.

Limitations of Use

The efficacy of Belimumab has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Belimumab has not been studied in combination with other biologics or intravenous cyclophosphamide. Use of Belimumab is not recommended in these situations.


Belimumab is for intravenous infusion only and must be reconstituted and diluted prior to administration. Do not administer as an intravenous push or bolus.

The recommended dosage regimen is 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Reconstitute, dilute and administer as an intravenous infusion only, over a period of 1 hour. The infusion rate may be slowed or interrupted if the patient develops an infusion reaction. The infusion must be discontinued immediately if the patient experiences a serious hypersensitivity reaction.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.